In other reports, non-lysosomal β-glucosidase (GBA2) hydrolyzed GlcCer to release ceramide and glucose on the cytoplasmic side of ER and golgi membrane, potentially affecting tumor drug resistance (58, 59). This evidence concerns the gene GBA2 and neoplasm.